The drug from Merck was OK’d for patients with artery-clogging cholesterol that persists even after taking statins.

This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory ...

Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way from a statin to lower cholesterol.

The Department of Pharmacy, Medical Supplies, Equipment, and Supplies, Ministry of Health of Hamad government has warned all ...

FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...

Add Yahoo as a preferred source to see more of our stories on Google. Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness' top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Please provide your email address to receive an email when new articles are posted on . The FDA approved belzutifan with pembrolizumab as an adjuvant therapy for adults with renal cell carcinoma. The ...

Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for a planned phase 3 study, completing the trio of contributors needed to run the colorectal cancer trial. California-based ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s best-selling medication. Mounjaro generated $8.7 billion for Lilly in the first ...